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Abstract 
Recently, thymidine monophosphate kinase (TMPK) emerged as an attractive target for 
developing inhibitors of Mycobacterium tuberculosis growth. The elucidation of the X-ray 
structure of TMPK of M. tuberculosis (TMPKmt), as well as the structure of an earlier 
serendipitously discovered dimeric thymidine inhibitor, laid the foundation for the design of 
potent and selective TMPKmt inhibitors reported here.  
Several hits identified within a series of 3’-C-branched thiourea-substituted -thymidine 
derivatives inspired us to construct a set of 5’-thiourea substituted -thymidine derivatives, 
characterized by a similar relative orientation of the thymine and arylthiourea moieties.  
-Thymidine derivative 15, featuring a (3-trifluoromethyl-4-chlorophenyl)thiourea moiety, 
has a Ki-value of 0.6 M and a selectivity index of 600 versus human TMPK. Moreover it 
represents the first TMPK inhibitor, showing good inhibitory activity on growing M. bovis 
(MIC99 = 20 g/mL) and M. tuberculosis (MIC50 = 6.25 g/mL) strains. 
 
Keywords: thymidine monophosphate kinase; nucleoside-analogues; Mycobacterium 
tuberculosis. 
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 Introduction 
At the beginning of the 21st century, tuberculosis (TB) remains a major public health issue, 
killing over 1.6 million people annually. TB is one of the world’s oldest infectious diseases 
and since the 1950’s there has been an effective, affordable and accessible cure for this 
disease. However, TB is resurging as a serious threat, mainly as a result of the synergism with 
HIV and the emergence of multi-drug resistant strains (MDR-TB).1 
The current treatment of TB requires an exceedingly lengthy therapy of 6-9 months, often 
involving a cocktail of three or four different drugs.2 Beside significant toxicity, the lengthy 
therapy also brings about poor patient compliance, which is a frequent source for selection of 
drug-resistant and often deadly MDR-TB bacteria. 
Especially HIV infection is a major synergistic risk factor for TB: it increases the chance for 
reactivation of latent Mycobacterium tuberculosis infection,3 but also enhances rapid TB 
progression soon after (re)infection with TB.4 Consequently, TB is one of the most common 
causes of death in HIV-positive adults living in less-developed countries.  
To face this expanding threat, extensive research for new antituberculosis agents has been 
performed, yet not yielding any new FDA-approved drug since the 1960s. The development 
of new drugs that shorten the long therapy as well as the discovery of new mycobacterial 
targets are necessary to eradicate strains being resistant to different types of drugs. An 
additional challenge in this search is the particularly impermeable nature of the lipid-rich 
mycobacterial cell wall,5 which causes the low uptake of active compounds in the 
mycobacteria and a very slow growth of the bacillus, resulting in long treatments required for 
complete sterilization. 
However, some interesting compounds are currently being evaluated in clinical trials.6 One of 
the most promising early drug candidates is a diarylquinoline derivative developed by 
Johnson and Johnson, which is proposed to inhibit F1F0 proton ATP synthase, a new target in 
mycobacteria.7 
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Another recently discovered target is thymidine monophosphate kinase (TMPKmt), which 
plays an essential and unique role in the DNA synthesis of this bacillus.8 The elucidation of 
the X-ray structure of human10 and mycobacterial11 TMPK and their low (22%) sequence 
identity further promotes TMPKmt as an attractive target for the development of selective 
inhibitors. 
Thymidine is a moderately potent inhibitor of TMPKmt (Ki ≈ 27 M). Both the sugar12, 13, 14 
and the base15, 16 moiety of thymidine have been the subject of different modifications to 
enhance affinity and selectivity for the bacterial enzyme. The most active TMPKmt inhibitors 
reported so far show Ki-values in the low micromolar range. Only recently we identified a 
TMPKmt inhibitor, derived from a 2’,3’-bicyclic thymidine analogue, that shows some 
activity against living mycobacteria cultures (MIC99 ≈ 100 gmL-1).17 
Lately, our group discovered an unusual dinucleoside 1 that produced significant inhibition of 
TMPKmt (Ki = 37 M).14 The second thymidine monomer attached to the 3’-position 
suggested the possibility to introduce large substituents at this position to fit in the thymidine 
monophosphate (dTMP)-pocket. Next to this surprising activity, compound 1 did not inhibit 
human TMPK (TMPKh) at 1 mM, creating opportunity for further explorations of this type of 
analogues (Figure 1).  
We investigated the possibility to replace one thymidine monomer by different substituted 
phenyl groups. Concurrently, thiocarlide,18 a drug that formerly proved efficient in treating 
TB,19, 20 inspired us to replace the connecting urea group by a thiourea linker, resulting in 3’-
branched thiourea-substituted -thymidine derivatives.  
By carefully selecting a limited set of compounds based on the Topliss’ tree,21 we aimed to 
assess the relative importance of the lipophilic, electronic and sterical properties of the aryl 
substituents. 
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Modelling studies on the binding mode of dinucleoside 1 to its target suggested that the 
second monomer binds to the area where normally the phosphoryl donor binds, in this way 
forcing the sugar ring to tilt over 180° compared to the natural substrate dTMP.12 Similarly, 
the envisaged -thiourea derivatives are expected to bind the dTMP-pocket upside down, 
positioning the aromatic 3’-substituent into the phosphoryl donor binding area, and the 
nucleobase below the sugar plane. 
As depicted in Figure 2, we hypothesized that the relative orientation of the nucleobase and 
the arylthiourea moiety in these β-thiourea derivatives might be imitated by 5’-substituted -
thymidine analogues. The fact that 5’-O-phosphorylated -thymidine was accepted by 
TMPKmt as a substrate (see further) confirmed that -nucleosides proved able to adopt the 
proposed binding mode, which incited us to synthesize the readily accessible 5’-deoxy-5’-N-
arylthiourea -thymidine derivatives.  
After a detailed exploration of the 5’-thiourea pattern, we assessed the importance of the 
deoxyribofuranose moiety by the synthesis of 2’,3’-dideoxy-, 2’,3’-dideoxydidehydro- and 
acyclic nucleoside derivatives. 
In an attempt to use adenosine to enhance the uptake in the mycobacterial cell,22, 23 a 
dinucleoside was designed, consisting of a -thymidine monomer connected to adenosine by 
a thioureum linker. 
 
Results and discussion 
Chemistry 
The synthesis of a series of 3’-C-branched--thiourea-derivatives started from -D-thymidine. 
Different methods are described for the synthesis of 3’-C-branched nucleosides.24, 25 A radical 
introduction of a -styrene residue appears to result in the shortest synthetic route (Scheme 1). 
Compound 34 was obtained following the procedure of Chu et al.26 This compound was 
treated with -tributylstannylstyrene and 2,2’-azabisisobutyronitrile in benzene to give 35. A 
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two-step one-pot reaction involving cis-dihydroxylation with osmium tetroxide and 4-
methylmorpholine N-oxide as cooxidant, followed by sodium periodate cleavage of the diol, 
resulted in an unstable aldehyde, which was immediately reduced with sodium borohydride in 
aqueous ethanol to afford 36. After mesylation of the primary alcohol, the azido group was 
introduced using sodium azide in DMF. Hydrogenation of 37 over Pd/C gave amine 38. This 
precursor was reacted with different isothiocyanates in a parallel fashion to give target 
compounds 2-8 after final deprotection of the silyl group. 
For the synthesis of -D-thymidine 5’-O-monophosphate (9), 3’,5’-O-diacetyl--thymidine 
was first anomerized to its -anomer (46) according to the procedure of Ward et al.,27 
followed by deprotection and conversion to the 5’-monophosphate using classical 
phosphorylation conditions (Scheme 2).  
The synthesis of 5’-substituted -thymidine derivatives started from -thymidine (47) which 
was converted to the 5’-deoxy-5’-(thio)urea-derivatives 10-27 as depicted in Scheme 3. 
Amide 30 (Table 2) was isolated as a side product upon treatment of 49 with 
benzoylisothiocyanate. 
3’-Deoxygenation was performed by converting the 3’-hydroxyl group of 48 to its mesylate 
ester (Scheme 4). Upon treatment with base, elimination yielded the unsaturated sugar in 
nucleoside 51. Hydrogenation over Pd/C gave the 2’,3’-dideoxy-analogue 52, while 
Staudinger reduction selectively converted the azide, affording the unsaturated amine 53. 
Final treatment of these amines with 3-CF3-4-Cl-isothiocyanate afforded thiourea derivatives 
28 and 29. 
Acyclic derivatives were synthesized following a procedure as reported for uridine-
derivatives by Danel et al.28 (Scheme 5). The primary alcohol of 54 was converted to different 
thiourea-compounds as described above. 
For the preparation of the adenosine-conjugate 33 (Scheme 6), 5’-amino-2’,3’-O-
isopropylidene adenosine (57) was treated with 1,1’-thiocarbonyldiimidazole to generate in 
 7
situ the isothiocyanate, which was further reacted with 5’-amino--thymidine (49) 29 to afford 
the envisioned dinucleoside after final deprotection of the acetonide. 
 
Biological evaluation 
All compounds have been evaluated for TMPKmt inhibition as described in the experimental 
section.  
For the 3’-C-branched--thymidine derivatives, analogue 2 with an unsubstituted phenyl ring 
showed a Ki-value of 69.0 M (Table 1). This value indicates a weaker binding to the enzyme 
than dinucleoside 1 (Ki = 37 M) and the natural substrate (Km = 4.5 M). However, this 
result suggests that this analogue can still be accommodated in the active pocket. In order to 
optimize the potency of this phenyl analogue, Topliss’ scheme21 was used. This decision tree 
is based on the concept, pioneered by Hansch,30 that principally the lipophilic, electronic and 
steric properties of the introduced substituent influence the biological activity. A 4-chloro-
substitution of the phenyl ring (3) resulted in a 3-fold increased activity. According to 
Topliss’ decision tree, this increase confirms the positive effect of lipophilic and electron 
withdrawing substituents on the inhibitory activity. This trend was validated by further 
improvement of the activity with a 3,4-dichloro-substitution pattern (6) which further 
increased activity by another 3-fold (Ki = 7.2 M). On the other hand, a 4-methoxy (4) or 4-
methyl substituent (5) resulted in a decreased activity. To further validate electron 
withdrawing properties, compound 8 was synthesized, while 7 should indicate if sterically 
more demanding substituents were also allowed. Compound 8 with a 3-CF3-4-Cl-substitution 
pattern was found to be the most potent inhibitor of this series with a Ki-value of 5.0 M, 
indicating that mainly the electronic features of the substituents positively influenced the 
inhibitory activity. 
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The good affinity observed amongst these -thiourea derivatives suggests a binding mode 
analogous to that described for dinucleoside 111 with the arylthiourea moiety occupying the 
phosphoryl donor binding site. 
As illustrated in Figure 2, a newly designed family of 5’-thiourea substituted -thymidine 
derivatives, was anticipated to bind in a similar way as the above described -thiourea 
compounds. Before moving on to the synthesis of these compounds, -thymidine 
monophosphate was synthesized to investigate if the anticapted binding mode of these 
compounds was practicable. -Thymidine monophosphate was indeed accepted as a substrate 
by TMPKmt (Km = 450 M, Vm = 0.77 U/mg at 2 mM ATP), thereby competing with dTMP 
(Ki= 15.0 M). Compared to the natural substrate however, the binding constant of this 
anomer was 10 times higher and its maximum velocity (Vm) only 7.5% of that of dTMP. The 
same broad stereoisomeric substrate specificity has been observed for mitochondrial 
thymidine kinase (TK2), deoxyguanosine kinase (dGK) and deoxycytosine kinase (dCK), 
which proved able to recognize -D and -L, as well as -D and -L nucleosides as a 
substrate.31 
In a next step, the 5’-thiourea substituted -nucleosides were synthesized. Their biological 
activities are represented in Table 2.  
In analogy to our observations for the 3’-C-branched -thymidine thiourea analogues, 
lipophilic and electronic withdrawing substituents favour high activity.  With a Ki of 0.6 M, 
analogue 15 (R1=Cl, R2= CF3) proved to be the most potent TMPKmt inhibitor reported so 
far. 
As the corresponding - and -thiourea derivatives were designed to bind in a similar fashion, 
a comparison between the corresponding activities is presented in Figure 3. 
The graph shows that the -derivatives are consistently (~ 4- to 5-fold) more active than the 
-congeners, and clearly reveals a similar trend in both series, further supporting our design 
hypothesis. 
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To illustrate the binding mode of the two main series of inhibitors, docking of two 
representative compounds 2 () and 10 () was performed. This experiment resulted in 50 
conformations, mainly containing two different orientations: one with the nucleobase stacking 
with Phe70 and one with the aromatic tail stacking to Phe70. As opposed to the former, the 
latter conformations preclude certain amino acids (e.g., Arg74, Asn100) to form H-bonds and 
were therefore rejected. This rejection is justified as docking showed that the space close to 
Phe70 is too small to accommodate bulky substituents like a Cl or a CF3 group. Moreover the 
docked conformations with the aromatic ring occupying the base site are shifted, reducing the 
stacking interaction and thus drastically limiting the number of meaningful conformations 
found.  
When comparing corresponding analogues from both series such as 2 and 10 (Figure 4), both 
the nucleobase and the arylthiourea-moiety occupy the same areas. For the -derivatives, the 
pyrimidine ring and Phe70 are arranged in a more parallel fashion compared to the -
derivatives, resulting in a stronger stacking. Moreover compound 10 is more favourably 
positioned to form an extra H-bond with Asp9 through a nitrogen of its thiourea function, 
which may contribute to the higher affinity of the -analogues for TMPKmt.  
Further structural modifications elucidated that small structural changes, such as introduction 
of an alkyl chain of 1 or 2 carbon atoms between the thioureum and phenyl, are well tolerated 
by TMPKmt,  yet not enhancing the affinity for the enzyme.  
It is found that the tail of molecules 10 and 24 points to the outside of the enzyme through a 
channel, in the same orientation as dinucleoside 1.12 This exit channel is surrounded by 
residues Arg14, Ala35, Phe36, Pro37, Tyr39, Arg160 (Figure 5). Adding functional groups in 
para- and meta-position on the phenyl ring seems to improve the activity, by increasing 
hydrophobic contact with these residues. However, since longer chains extend more out of the 
enzyme into the solvent (Figure 5), this indicates that no further improvement can be obtained 
by increasing the linker length. 
 10
Surprisingly, sterically demanding substituents as in 19 and 21 cause almost no change in 
inhibitory activity, so most likely a large pocket around the phosphoryl donor area is available 
for the inhibitor to interact with. The activity of fluoresceine-labelled compound 19 opens 
interesting perspectives for its use in the enzymatic activity determination or in mycobacterial 
uptake-studies. The lower activity of compounds 16 and 17 suggests a role for the aromatic 
moieties to stabilize the enzyme-inhibitor complex. 
To check the importance of the hydrophobic sulphur of the thiourea linkage, urea derivatives 
26 and 27 were synthesized.  As those compounds retain their good affinity for the enzyme, a 
larger structural freedom for the linkage between the aromatic moiety and the nucleobase 
seems to be tolerated.  
Only a small drop in affinity was observed upon removal of the 3’-hydroxyl (28) or upon 
additional introduction of a double bond between 2’ and 3’ (29). We therefore conclude that 
the most important feature for TMPKmt inhibition of this series is the relative orientation of 
the nucleobase and the 5’-substituent, combined with the ability of the 5’-substituent to 
interact with the enzyme active site pocket. 
This led us to synthesize acyclic derivatives 31 and 32, which exhibited only a very weak 
affinity for the enzyme. Despite the fact that the number of bonds between the thymine and 
the aromatic moiety is retained in these structures, the higher entropy changes required to 
form the complex are likely to be unfavourable for binding.   Moreover, when comparing the 
acyclic derivatives with compound 10, an important hydrogen bond at the 3’-position is lost, 
which may additionally cause the lack of activity. 
The selectivity of the most potent TMPKmt vis-à-vis the human isozyme was investigated. 
Most tested compounds proved highly selective for the mycobacterial enzyme. Especially 
compound 15, the most active compound of the series, showed a selectivity index of 600, 
indicating that the inverse binding mode of the sugar is not tolerated by the human enzyme. 
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Consequently, we assessed the potential of the most promising analogues to restrain 
mycobacterial growth. Whereas compound 15 proved to be the most potent TMPKmt 
inhibitor, it also proved superior in a M. bovis growth inhibition assay. Selected compounds 
were also tested for their capability to reduce M. tuberculosis H37Rv growth at a concentration 
of 6.25 g/mL, showing an inhibition of bacterial growth between 34 and 55% at this 
concentration. 
For the first time, TMPKmt inhibitors proved capable to inhibit the growth of both M. bovis 
and M. tuberculosis, confirming that TMPKmt indeed represents a valuable target for 
designing antituberculosis drugs. Moreover, the compounds were found non-toxic in Vero cell 
cultures at 100 µM and also devoid of appreciable inhibitory activity against a broad variety 
of viruses including herpes simplex virus type 1 (KOS) and type 2 (G), vaccinia virus, 
vesicular stomatitis virus, Sindbis virus, reovirus-1, parainfluenza virus-3, Coxsackie B4, 
respiratory syncytial virus, Punta Toro virus, feline coronavirus, influenza virus A (H1N1 and 
H3N1) and influenza virus B. This lack of activity further points to the highly selective 
activity of several compounds against mycobacteria. 
Very recently, a series of 5’-modified adenosine derivatives has been discovered as powerful 
siderophore biosynthesis inhibitors.22, 23 Some of these analogues showed MIC99-values 
against M. tuberculosis H37Rv comparable to that of isoniazid, suggesting the presence of 
active adenosine-uptake mechanism.  For this reason, conjugate 33 was synthesized to exploit 
this proposed adenosine uptake mechanism to enhance antimycobacterial activity. While still 
showing moderate TMPKmt inhibitor activity, dinucleoside 33 failed to inhibit mycobacterial 
growth. 
Finally, all compounds tested in Vero cell cultures were devoid of cytotoxicity at 100 M, 
while another assay proved 15 to have a minimum cytotoxic concentration of 300-400 g/mL, 
more than 10 times the concentration needed to kill M. bovis. The urea analogues (26 and 27) 
of the most active compounds (14 and 15), which lack the thiourea moiety, earlier described 
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as the perpetrator of toxicity,38 showed nearly equal inhibitory activity against TMPKmt, 
while still retaining a sufficient selectivity versus the human enzyme (with SI= 90-105) and 
interesting inhibitory activity on the growing M. bovis and M. tuberculosis strains. 
 
Conclusion 
Based on the structure of the recently discovered dinucleoside 1 as a selective TMPKmt 
inhibitor, this paper describes the synthesis and biological evaluation of a series of 3’-C-aryl 
thiourea derivatives of -D-thymidine. Optimisation of the aryl thiourea led to analogue 8 
that, with a Ki-value of 5.0 M, clearly surpassed 1 in inhibitory activity. 
Modelling experiments suggested a distinct binding mode for these analogs, as compared to 
the natural substrate: the sugar moiety binds the active site upside down. The acceptance of -
thymidine-5’-phosphate as a substrate for TMPKmt supported the synthesis of 5’-substituted 
-thymidine thiourea derivatives, mainly characterized by a similar relative orientation of the 
5’-aryl moiety and the nucleobase.   
This led to the discovery of compound 15 as the most promising compound of this series with 
a Ki-value of 0.6 M, a selectivity index (versus TMPKh) of 600, and a good inhibitory 
activity on the growing M. bovis (MIC99 = 20 g/mL) and M. tuberculosis (39% inhibition at 
6.25 g/mL) strains. 
Next to the relative orientation between the aryl moiety and the nucleobase, structural 
exploration of the -thymidine derivatives, revealed the positive impact of electronic 
withdrawing and lipophilic substituents on the 5’-aryl moiety and the need for aromatic 
residues at this 5’-position.  
In conclusion, we have designed, synthesized, and evaluated a series of nucleoside inhibitors 
of M. tuberculosis TMPK, which resulted in the identification of 5’-arylthiorea α-thymidine 
analogues endowed with significant inhibitory activity against M. tuberculosis and M. bovis 
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growth and low cytotoxicity. This strategy represents a promising approach for the 
development of a new class of antibiotics effective for the treatment of TB.  
In a broader sense, this study opens interesting perspectives for using sugar-modified -
nucleosides as readily accessible scaffolds for the rational design of biologically important 
tool compounds acting on other kinase targets or in other areas in chemical biology. 
 
Acknowledgements 
Antimycobacterial data were provided by the Tuberculosis Antimicrobial Acquisition and 
Coordinating Facility (TAACF) through a research and development contract with the U.S. 
National Institute of Allergy and Infectious Diseases. The authors thank the BOF (Bijzonder 
Onderzoeksfonds Universiteit Gent, Research Fund Ghent University) and the FWO (Fonds 
voor Wetenschappelijk Onderzoek - Vlaanderen, Fund for Scientific Research – Flanders), 
Pasteur Institute (GPH tuberculose), INSERM and CNRS for financial support of this 
research. 
 
Experimental section 
Spectrophotometric binding assay 
The in vitro tests were done on TMPKmt and TMPKh, recombinant enzymes overexpressed 
in E. coli. TMPKmt and TMPKh activity was determined using the coupled 
spectrophotometric assay described by Blondin et al.39 using an Eppendorf ECOM 6122 
photometer and a wavelength of 334 nm. The reaction medium (0.5 mL final volume) 
contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM 
phosphoenol pyruvate kinase and 2 units each of lactate dehydrogenase, pyruvate kinase and 
nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept at a constant 
level of 0.5 mM and 0.05 mM respectively, whereas the concentrations of analogues varied 
between 0.01 and 2 mM. For the Km determination of the 5’-phosphate derivatives, the ATP 
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concentration was kept constant at 2 mM and the compound concentration varied between 0.1 
and 1 mM. 
 
Biological assays on Mycobacterium bovis (BCG) 
The different compounds were assayed for their inhibitory potency on Mycobacterium bovis 
var.BCG growth in vitro.40 A micro-method of culture was performed in 7H9 Middlebrook 
broth medium containing 0.2% glycerol, 0.5% Tween 80 and supplemented with oleic acid, 
albumin, dextrose and catalase (Becton-Dickinson). Serial two-fold dilutions of each 
compound were prepared directly in 96-well plates. The bacterial inoculum was prepared 
previously at a concentration in the range of 107 bacteria (M. bovis BCG 1173P2) in 7H9 
medium and stored at –80 °C until used. The bacteria, adjusted at 105 per ml, were delivered 
in 100µl per well. The covered plates were sealed with Parafilm and incubated at 37 °C in 
plastic boxes containing a humidified normal atmosphere. At day 8 of incubation, 30 µl of a 
resazurin (Sigma) solution at 0.01% (wt/vol) in water were added to each well. After an 
overnight incubation at 37 °C the plates were assessed for colour development using the 
optical density difference at 570 nm and 630nm on a ELISA reader. The change from blue to 
pink indicates reduction of resazurin and therefore bacterial growth. The lowest compound 
concentration that prevented the colour change determined the MIC for the assayed 
compound. 
 
Biological assays on Mycobacterium tuberculosis H37Rv 
The screening test against M. tuberculosis H37Rv was conducted at 6.25 mg/mL in BACTEC 
12B medium using the Microplate Alamar Blue Assay (MABA).41 
 
Cytotoxic activity of test compounds in Vero cell cultures 
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To monolayers of confluent Vero cell cultures in 96-well microtiter plates were added serial 
dilutions of the test compounds (total volume of compound-containing culture medium: 200 
µl). After 3 days of incubation at 37°C in a humidified CO2-controlled atmosphere, the cell 
cultures were microscopically inspected for morphological alteration. The MCC was defined 
as the compound concentration required to cause a microscopical alteration of the mock-
infected cell cultures at day 3 post compound administration. 
 
Molecular Modelling 
The published X-ray structure of the TMPKmt (PDB entry 1G3U)11 was used in all docking 
experiments. The inhibitors 2, 10 and 24 were drawn using JChemPaint42 and BUILD3D.43 
The molecular geometry was fed into gamess for geometry optimization using the AM1 force 
field.44 The sugar conformation in 2 was modelled as C2’-endo with the base in an equatorial 
orientation by replacing the sugar and base fragments of thymidine monophosphate from the 
pdb file 1G3U.45 The sugar-base in 10 and 24 was replaced by the sugar-base in CSD46 entry 
LEDRIV47 having the base in α-position and equatorial orientation. Polar hydrogen atoms 
were added to the enzyme and inhibitor structures using autodocktools.48 The compounds 
were docked in the cavity close to Tyr-70 by means of the Autodock 3.05 software.49 The top 
50 of docked ligand conformations was examined and a manual selection procedure was used 
to validate the docked conformations.  
 
Synthesis 
General 
NMR spectra were obtained with a Varian Mercury 300 spectrometer. Chemical shifts are 
given in ppm () relative to residual solvent peak, in the case of DMSO-d6 2.54 ppm for 1H 
and 40.5 ppm for 13C, in the case of CDCl3 7.26 ppm for 1H and 77.4 ppm for 13C. All signals 
assigned to hydroxyl groups were exchangeable with D2O. Mass spectra and exact mass 
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measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight 
(Q/oaTOF) tandem mass spectrometer (qT of 2, Micromass, Manchester, U.K.) equipped with 
a standard electrospray ionization (ESI) interface. Samples were infused in a 2-propanol/water 
(1:1) mixture at 3 L/min. Precoated Merck silica gel F254 plates were used for TLC, and 
spots were examined under UV light at 254 nm and further visualized using a sulphuric acid-
anisaldehyde spraying reagent. Column chromatography was performed on ICN silica gel 
(63-200 m, ICN, Asse Relegem, Belgium). 
 
5’-O-tert-Butyldiphenylsilyl-3’-deoxy-3’-O-((E)-2-phenylethenyl)thymidine (35) 
To a solution of carbonothioate 34 (7.3 g, 11.85 mmol) in benzene (40 mL) was added -
tributylstannylstyrene (11.64 g, 29.62 mmol) in 20 mL benzene. The resulted solution was 
degassed with nitrogen during 30 minutes at room temperature and during the same time at 45 
°C. 2,2’-Azabisisobutyronitrile (AIBN) (583 mg, 3.56 mmol) was added and the solution was 
refluxed for 2 h. A second portion of AIBN (583 mg, 3.56 mmol) was added after cooling the 
reaction mixture to 40 °C. The reaction mixture was refluxed again for 2 h. This procedure 
was repeated during 72 hours. After evaporation of the solvent, the residue was purified by 
column chromatography (hexane/ethyl acetate 85:15) to give 35 as an oil (1.8 g, 24%). 
1H NMR (300 MHz, CDCl3):  1.05 (9H, s, tert-butyl), 1.54 (3H, s, 5-CH3), 2.22-2.40 (2H, m, 
H-2’ and H-2”), 3.26 (1H, m, H-3’), 3.85 (1H, m, H-4’), 4.10 (2H, m, H-5’ and H-5”), 5.98 
(1H, dd, J= 8.4 and 15.9 Hz, CH-6’), 6.19 (1H, dd, J= 3.3 and 7.2 Hz, H-1’), 6.50 (1H, d, J= 
15.6 Hz, CH-Ph), 7.25-7.41 (11H, m, 11 arom H), 7.55 (1H, d, J= 1.2 Hz, H-6), 7.67 (4H, m, 
arom H), 8.21 (1H, br s, N(3)H); HRMS (ESI-MS) for C34H38N2O4SiNa [M+Na]+ found, 
589.2492; calcd, 589.2499. 
 
5’-O-tert-Butyldiphenylsilyl-3’-deoxy-3’-(hydroxymethyl)thymidine (36) 
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To a mixture of 35 (1.8 g, 3.11 mmol) and 4-methylmorpholine N-oxide (546 mg, 4.66 mmol) 
in dioxane (50 mL) was added an aqueous solution of OsO4 (1 mL, 0.16 mmol, 1% in water). 
After stirring overnight at room temperature under light protection, the reaction was 
completed. Sodium periodate (1.33 g, 6.22 mmol) was added and after 2 h the reaction was 
completed. The mixture was diluted with ethyl acetate, filtered through a Celite path and 
solids were washed with ethyl acetate. The combined filtrates were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. To the resulting crude aldehyde 
dissolved in ethanol/water (4:1; 45 mL) at 0 °C was added NaBH4 (540.8 mg, 14.3 mmol) in 
small portions. After 2 h at room temperature, the reaction mixture was diluted with ethyl 
acetate and washed with water. The organic layer was dried over MgSO4 and concentrated to 
dryness. After purification by column chromatography (CH2Cl2/MeOH 97:3), the title 
compound (900 mg, 59% from 35) was isolated as a white foam. 
1H NMR (300 MHz, DMSO-d6):  1.00 (9H, s, tert-but), 1.49 (3H, s, 5-CH3), 2.03-2.19 (2H, 
m, H-2’ and H-2”), 2.48 (under DMSO-signal, H-3’), 3.43 (2H, d, J= 5.1 Hz, H-6’ and H-6”), 
3.77 ( 1H, dd, J= 4.2 and 10.5 Hz, H-5’), 3.86-3.95 (2H, m, H-4’ and H-5”), 4.77 (1H, br s, 
6’-OH), 6.03 (1H, dd, J= 5.4 and 6.6 Hz, H-1’), 7.37-7.44 (7H, m, 6 arom H and H-6), 7.61-
7.64 (4H, m, 4 arom H), 11.23 (1H, br s, N(3)H); HRMS (ESI-MS) for C27H34N2O5SiNa 
[M+Na]+ found, 517.2139; calcd, 517.2134. 
 
3’-(Azidomethyl)-5’-O-tert-butyldiphenylsilyl-3’-deoxythymidine (37) 
Methanesulfonyl chloride (0.366 mL, 4.73 mmol) was added to a solution of 36 (900 mg, 1.82 
mmol) in pyridine (10 mL) at 0 °C. The reaction was stirred at 0 °C during 1 h. The mixture 
was diluted with CH2Cl2 (25 mL), washed with saturated aqueous NaHCO3 and dried over 
MgSO4. The solvent was evaporated in vacuo to give the crude mesylate. The obtained 
residue was dissolved in DMF (50 mL) and treated with NaN3 (1.18 g, 18.2 mmol) at 60 °C. 
After 7 h the reaction was completed. The reaction mixture was evaporated to dryness and the 
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residue was dissolved in CH2Cl2 (25 mL). The organic layer was washed with water, dried 
over MgSO4 and evaporated to give a syrup which was purified by column chromatography 
(CH2Cl2/MeOH 99:1) yielding 37 (915 mg, 97%) as a white foam. 
1H NMR (300 MHz, DMSO-d6):  1.00 (9H, s, tert-but), 1.50 (3H, d, J= 0.6 Hz, 5-CH3), 2.15 
(2H, m, H-2’ and H-2”), 2.62 (1H, m, H-3’), 3.42-3.57 (2H, m, H-6’ and H-6”), 3.77-3.85 
(2H, m, H-4’ and H-5’), 3.93 (1H, m, H-5”), 6.06 (1H, t, J= 6.6 Hz, H-1’), 7.36-7.45 (7H, m, 
6 arom H and H-6), 7.61-7.65 (4H, m, 4 arom H), 11.28 (1H, br s, N(3)H); HRMS (ESI-MS) 
for C27H33N5O4SiNa [M+Na]+ found, 542.2197; calcd, 542.2199. 
 
3’-(Aminomethyl)-5’-O-tert-butyldiphenylsilyl-3’-deoxythymidine (38) 
A solution of 37 (915 mg, 1.76 mmol) in methanol (50 mL) was hydrogenated under 
atmospheric pressure for 5 hours in the presence of 10 % Pd/C (90 mg). The catalyst was 
removed by filtration through a Celite path and the filtrate was evaporated to give pure 
compound 38 (860 mg, 99%). 
1H NMR (300 MHz, DMSO-d6):  1.00 (9H, s, tert-but), 1.48 (3H, d, J= 0.9 Hz, 5-CH3), 
2.03-2.19 (2H, m, H-2’ and H-2”), 2.32 (1H, m, H-3’), 2.57 (2H, dd, J= 3.9 and 5.7 Hz, H-6’ 
and H-6”), 3.74-3.85 (2H, m, H-4’ and H-5’), 3.93 (1H, dd, J= 2.4 and 10.8 Hz, H-5”), 6.02 
(1H, dd, J= 5.1 and 6.9 Hz, H-1’), 7.37-7.43 (7H, m, 6 arom H and H-6), 7.61-7.65 (4H, m, 4 
arom H); HRMS (ESI-MS) for C27H36N2O4Si [M+H]+ found, 494.2478; calcd, 494.2474. 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-phenylthiourea (39) 
To a solution of 38 (55 mg, 0.11 mmol) in DMF (1 mL), phenylisothiocyanate (15 mg, 0.11 
mmol) in 1 mL DMF was added at 0 °C. The reaction mixture was stirred during 1 h. The 
solvent was evaporated to dryness and the residue was purified by column chromatography 
(CH2Cl2/MeOH 98:2) affording thiourea 39 (48 mg) in 70% yield. 
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1H NMR (300 MHz, DMSO-d6):  0.99 (9H, s, tert-but), 1.45 (3H, s, 5-CH3), 2.17 (2H, m, H-
2’ and H-2”), 2.83 (1H, m, H-3’), 3.51-3.67 (2H, m, H-6’ and H-6”), 3.80-3.93 (3H, m, H-5’, 
H-4’ and H-5”), 6.08 (1H, t, J= 5.4, H-1’), 7.10 (1H, t, J= 7.2 Hz, 1 arom H), 7.26-7.43 (11H, 
m, 10 arom H and H-6), 7.61-7.66 (4H, m, 4 arom H), 7.93 (1H, br s, N(6’)H), 9.55 (1H, br s, 
N(ar)H), 11.27 (1H, br s, N(3)H); HRMS (ESI-MS) for C34H41N4O4SSi [M+H]+ found, 
629.2618; calcd, 629.2617. 
 
N-[(3’-Deoxythymidin-3’-yl)methyl]-N’-phenylthiourea (2) 
Compound 39 (48 mg, 0.08 mmol) was dissolved in THF (4 mL). A solution of 1 M tetra-
nbutylammonium fluoride in THF (4 mL) was added. After 1 h at room temperature the 
reaction was completed. The solvent was evaporated, and the dry residue was purified by 
column chromatography (CH2Cl2/MeOH 97:3) to give pure compound 2 (27 mg) in 87% 
yield. 
1H NMR (300 MHz, DMSO-d6):  1.75 (3H, s, 5-CH3), 2.11 (2H, m, H-2’ and H-2”), 2.57 
(1H, m, H-3’), 3.51-3.78 (5H, m, H-4’, H-5’, H-5”, H-6’ and H-6”), 5.10 (1H, t, J= 5.1 Hz, 
5’-OH), 5.99 (1H, t, J= 4.8, H-1’), 7.09 (1H, t, J= 7.2 Hz, ar-H), 7.30 (2H, t, J= 7.5 Hz, 2 
arom H), 7.38 (2H, d, J= 7.5 Hz, 2 arom H), 7.85 (1H, s, H-6), 7.95 (1H, br s, N(6’)H), 9.60 
(1H, br s, N(ar)H), 11.22 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6): 12.99 (5-CH3), 
36.73 (C-2’), 38.10 (C-3’), 45.85 (C-6’), 62.09 (C-5’), 84.57 and 84.63 (C-4’ and C-1’), 
109.38 (C-5), 124.02 (arom C), 125.03 (arom C), 129.34 (arom C), 137.03 (C-6), 139.76 
(arom C), 151.07 (C-4), 164.54 (C-2), 181.39 (C=S); HRMS (ESI-MS) for C18H22N4O4SNa 
[M+Na]+ found, 413.1246; calcd, 413.1259. Anal. (C18H22N4O4S) C, H, N. 
 
-D-Thymidine (47) 
3’,5’-Di-O-acetyl--thymidine25 (4.54 g, 13.91 mmol) was dissolved in 150 mL NH3 in 
MeOH (7N solution). The reaction mixture was stirred at room temperature overnight. The 
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solvent was evaporated, the residue was dissolved in ethyl acetate and extracted with water 
three times, yielding 3.30 g of pure compound 47 (98%). 
1H NMR (300 MHz, DMS0):  1.78 (3H, d, J= 1.2 Hz, 5-CH3), 1.84-1.91 (1H, ddd, J= 3.0 
and 14.4 Hz, H-2’), 2.48-2.60 (1H, m, H-2”), 3.39 (2H, t, J= 5.2 Hz, H-5’ and H-5”), 4.13 
(1H, m, H-3’), 4.23 (1H, m, H-4’), 4.81 (1H, t, J= 5.7 Hz, 5’-OH), 5.30 (1H, d, J= 3.0 Hz, 3’-
OH), 6.12 (1H, dd, J= 3.3 and 7.5 Hz, H-1’), 7.75 (1H, d, J= 1.2 Hz), 11.20 (1H, br s, N(3)H); 
HRMS (ESI-MS) for C10H15N2O5 [M+H]+ found, 243.0975; calcd, 243.0981. 
 
-D-Thymidine 5’-monophosphate (9) 
A solution of -D-thymidine (150 mg, 0.62 mmol) in trimethyl phosphate (6.2 mL) was 
cooled to 0 °C, POCl3 (369 L, 4.03 mmol) was added dropwise and the mixture was stirred 
for 4 hours at 0 °C and for 30 minutes at room temperature. The mixture was poured into ice-
water (12 mL), neutralised with concentrated NH4OH and evaporated to dryness. The 
resulting residue was purified by column chromatography (iPrOH/NH4OH/H2O 77.5:15:2.5). 
Further purification was performed by HPLC (C-18, CH3CN/MeOH/0.05% HCOOH in H2O 
45:45:10, 3 mL/min). After lyophilisation of the collected pure fractions compound 9 was 
obtained (123 mg, 62%) as a white powder. 
1H NMR (300 MHz, D2O-d6):  1.81 (3H, d, J= 0.9 Hz, 5-CH3), 2.02-2.09 (2H, ddd, J= 3.0 
and 14.7 Hz, H-2’), 2.66-2.76 (1H, m, H-2”), 3.78 (2H, app t, J= 5.1 Hz, H-5’ and H-5”), 4.43 
(2H, m, H-3’ and H-4’), 6.12 (1H, dd, J= 3.0 and 7.2 Hz, H-1’), 7.68 (1H, d, J= 0.9 Hz, H-6); 
31P-NMR (500 MHz, D20):  2.97; 13C NMR (75 MHz, D2O-d6):  11.73 (5-CH3), 39.49 (C-
2’), 64.67 (C-5’), 71.20 (C-3’), 87.38 and 87.81 (C-4’ and C-1’), 110.75 (C-5), 138.39 (C-6), 
151.76 (C-4), 166.97; HRMS (ESI-MS) for C10H14N2O8PNa [M+Na]+ found, 345.0477; 
calcd, 345.0464; Anal. (C10H14N2O8P) C, H, N. 
 
5’-Azido-5’-deoxy--D-thymidine (48) 
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To a solution of -D-thymidine 47 (886 mg, 3.66 mmol) in pyridine (13.5 mL) at -78 °C, 
methanesulfonyl chloride (256 µL, 0.41 mmol) was added. The reaction mixture was stirred 
for 1 h at 0 °C. The reaction was quenched by adding saturated aqueous NaHCO3-solution 
and extracted with CH2Cl2 three times, dried over MgSO4 and evaporated. The residue was 
purified by column chromatography (CH2Cl2/MeOH 98:2) to give the mesylated compound 
(916 mg, 78%). 
1H NMR (300 MHz, DMSO-d6): 1.75 (3H, s, 5-CH3), 1.95 (1H, m, H-2’), 2.55 (1H, m, H-2”), 
3.19 (3H, s, CH3SO2), 4.12-4.26 (3H, m, H-5’, H-5” and H-3’), 4.33 (1H, m, H-4’), 5.58 (1H, 
br s, 3’-OH), 6.12 (1H, dd, J= 4.4 and 7.6 Hz, H-1’), 7.73 (1H, s, H-6), 11.27 (1H, br s, 
N(3)H); HRMS (ESI-MS) for C11H17N2O7S [M+H]+ found, 321.0759; calcd, 321.0756.  
 
A solution of 5’-mesylated -D-thymidine (916 mg, 2.88 mmol) and NaN3 (1.87 g, 29 mmol) 
in DMF (50 mL) was heated to 60 °C overnight. The reaction mixture was evaporated in 
vacuo. The residue was resolved in CH2Cl2 and washed with H2O. The organic layer was 
dried over MgSO4, evaporated and purified by column chromatography (CH2Cl2/MeOH 98:2) 
to afford compound 48 (672 mg, 87%).  
1H NMR (300 MHz, DMSO-d6): 1.76 (3H, s, 5-CH3), 1.93 (1H, m, H-2’), 2.51 (1H, m, H-2”), 
3.49 (2H, m, H-5’ and H-5”), 4.12 (1H, dd, H-3’), 4.24 (1H, m, H-4’), 5.50 (1H, br s, 3’-OH), 
6.13 (1H, dd, J= 4.5 and 7.5 Hz, H-1’), 7.72 (1H, s, H-6), 11.26 (1H, br s, N(3)H). HRMS 
(ESI-MS) for C10H14N5O4 [M+H]+ found, 268.1045; calcd, 268.1046. Anal. (C10H13N5O4) C, 
H, N. 
 
5’-Amino-5’-deoxy--D-thymidine (49) 
A solution of azide 48 (531 mg, 1.99 mmol) in methanol (30 mL) was hydrogenated under 
atmospheric pressure for 6 hours in the presence of 10% Pd/C (53.1 mg). The catalyst was 
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removed by filtration through Celite and the filtrate was evaporated to yield pure amine 49 
(471 mg, 98%). 
1H NMR (300 MHz, DMSO-d6): 1.74 (3H, s, 5-CH3), 1.85 (1H, m, H-2’), 2.49 (1H, m, H-2”), 
3.43 (2H, m, H-5’ and H-5”), 4.02 (1H, m, H-3’), 4.14 (1H, m, H-4’), 5.27 (1H, br s, 3’-OH), 
6.05 (1H, dd, J= 3.3 and 7.5 Hz, H-1’), 7.69 (1H, s, H-6), 11.24 (1H, br s, N(3)H). HRMS 
(ESI-MS) for C10H16N3O4 [M+H]+ found, 242.1134; calcd, 242.1141. Anal. 
(C10H15N3O4.1/2H2O) C, H, N; C: calcd, 47.99; found, 48.46. 
 
N-(5’-Deoxy--D-thymidin-5’-yl)-N’-phenylthiourea (10) 
For the synthesis of compound 10, compound 49 (54 mg, 0.22 mmol) was dissolved in DMF 
(2 mL). At 0 °C, phenyl isothiocyanate (36 mg, 0.26 mmol) was added and the reaction 
mixture was allowed to stir at room temperature during 3 h. After completion of the reaction, 
the reaction mixture was evaporated to dryness and the residue was purified by column 
chromatography (CH2Cl2/MeOH 97:3) to obtain the pure final compound 10 (69 mg, 83%). 
1H NMR (300 MHz, DMSO-d6):  1.77 (3H, d, J= 1.2 Hz, 5-CH3), 1.89-1.98 (1H, ddd, J= 3.3 
and 14.1 Hz, H-2’), 2.53-2.63 (1H, m, H-2”), 3.49 (1H, m, H-5’), 3.64 (1H, m, H-5”), 4.22 
(1H, m, H-3’), 4.34 (1H, m, H-4’), 5.47 (1H, d, J= 3.3 Hz, 3’-OH), 6.18 (1H, dd, J= 3.6 and 
8.1, H-1’), 7.10 (1H, t, J= 7.2 Hz, arom H), 7.32 (2H, t, J= 7.5 Hz, 2 arom H), 7.77 (2H, d, J= 
1.2 Hz, H-6 + N(5’)H), 9.63 (1H, br s, N(ar)H), 11.26 (1H, br s, N(3)H); 13C NMR (75 MHz, 
DMSO-d6):  13.03 (5-CH3), under DMSO (C-2’), 46.18 (C-5’), 71.58 (C-3’), 85.40 (C-1’), 
86.57 (C-4’), 109.51 (C-5), 123.83 (arom C), 124.97 (arom C), 129.29 (arom C), 137.68 (C-
6), 139.84 (arom C), 151.21 (C-4), 164.55 (C-2), 181.41 (C=S); HRMS (ESI-MS) for 
C17H21N4O4S [M+H]+ found, 377.1279; calcd, 377.1283; Anal. (C17H20N4O4S) C, H, N. 
 
N-(5’-Deoxy--D-thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorobenzyl)thiourea (23) 
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4-Chloro-3-trifluoromethylbenzylamine (65 mg, 0.31 mmol) was added at 0°C to a stirred 
solution of 1,1’-thiocarbonyldiimidazole (61 mg, 0.34 mmol) and imidazole (6.3 mg, 0.09 
mmol) in 4 mL acetonitril.  After 10 minutes at 0°C, the reaction was allowed to stir for 3 
hours at room temperature.  A solution of 49 (75 mg, 0.31 mmol) in 2 mL DMF was added 
and the reaction mixture was stirred at room temperature during overnight.  The reaction 
mixture was evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 
99:1) to obtain compound 23 (114 mg, 75%). 
1H NMR (300 MHz, DMSO-d6):  1.77 (3H, d, J= 0.9 Hz, 5-CH3), 1.87-1.95 (1H, ddd, J= 2.9 
and 14.4 Hz, H-2’), 2.50-2.60 (1H, m, H-2”), 3.47 (1H, m, H-5’), 3.55 (1H, m, H-5”), 4.18 
(1H, m, H-3’), 4.26 (1H, m, H-4’), 4.71 (2H, d, J= 4.8 Hz, CH2NH), 5.41 (1H, d, J= 3.0 Hz, 
3’-OH), 6.14 (1H, dd, J= 3.2 and 7.6 Hz, H-1’), 7.56 (1H, dd, J = 2.0 and 8.8 Hz, arom H), 
7.65 (1H, d, J = 8.7 Hz, arom H), 7.73 (2H, app s, arom H and H-6), 7.78 (1H, t, J = 4.7 Hz, 
N(5’)H), 8.14 (1H, d, J= 4.9 Hz, CH2NH), 11.20 (1H, br s, N(3)H); 13C NMR (75 MHz, 
DMSO-d6):  13.00 (5-CH3), 31.47 (CH2NH), 46.48 (C-2’), 46.58 (C-5’), 71.58 (C-3’), 85.46 
(C-1’), 86.98 (C-4’), 109.44 (C-5), 127.10 (arom C), 127.17 (arom C), 129.49 (arom C), 
132.14 (arom C), 133.57 (arom C), 137.58 (C-6), 140.54 (arom C), 151.19 (C-4), 164.52 (C-
2), 182.28 (C=S); HRMS (ESI-MS) for C19H21N4O4SClF3 [M+H]+ found,; calcd, 493.0924; 
Anal. (C19H20N4O4SClF3) C, H, N. 
 
N-(3,4-Dichlorophenyl)-N’-(5’-deoxy--D-thymidin-5’-yl)urea (26) 
Urea 26 was synthesized from 49 (85 mg, 0.35 mmol) and 3,4-dichlorophenyl isocyanate (79 
mg, 0.42 mmol) using the same procedure as described for the synthesis of 10. After 
purification by column chromatography (CH2Cl2/MeOH 97:3), compound 26 (113 mg, 75%) 
was obtained. 
1H NMR (300 MHz, DMSO-d6):  1.78 (3H, s, 5-CH3), 1.89-1.97 (1H, ddd, J= 3.2 and 14.3 
Hz, H-2’), 2.51-2.61 (1H, m, H-2”), 3.09 (1H, m, H-5’), 3.21 (1H, m, H-5”), 4.16 (2H, m, H-
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3’ and H-4’), 5.42 (1H, d, J= 3.3 Hz, 3’-OH), 6.15 (1H, dd, J= 3.6 and 7.8, H-1’), 6.44 (1H, t, 
J= 5.1 Hz, N(5’)H), 7.22 (1H, dd, J= 2.4 and 9.0 Hz, arom H), 7.43 (1H, d, J= 9.0 Hz, arom 
H), 7.75 (1H, d, J= 0.9 Hz, H-6), 7.82 (1H, d, J= 2.4 Hz, arom H), 8.92 (1H, br s, N(ar)H), 
11.24 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6):  12.99 (5-CH3), 41.77 (C-2’), 
49.28 (C-5’), 71.57 (C-3’), 85.35 (C-1’), 87.32 (C-4’), 109.54 (C-5), 118.40 (arom C), 119.36 
(arom C), 122.97 (arom C), 131.12 (arom C), 131.61 (arom C), 137.60 (C-6), 141.33 (arom 
C), 151.21 (C-4), 155.56 (C=O), 164.51 (C-2); HRMS (ESI-MS) for C17H18N4O5Cl2Na 
[M+Na]+ found, 451.0548; calcd, 451.0552; Anal. (C17H18Cl2N4O5) C, H, N. 
 
5’-Azido-5’-deoxy--D-thymidine 3’-methanesulfonate (50) 
Compound 48 (400 mg, 1.5 mmol) was dissolved in pyridine (5 mL) and 
methanesulphonylchloride (150 L, 1.95 mmol) was added at 0 °C. After 2h, the reaction was 
quenched by saturated NaHCO3-solution (5 mL) and extracted with CH2Cl2 (3x 10 mL). The 
combined organic layers were dried with MgSO4 and evaporated to dryness, to obtain pure 
compound 50 (420 mg, 81%). 
1H NMR (300 MHz, DMSO-d6):  1.77 (3H, d, J= 1.0 Hz, 5-CH3), 2.32-2.40 (1H, ddd, J= 3.6 
and 15.0 Hz, H-2’), 2.81-2.91 (1H, m, H-2”), 3.27 (3H, s, SO2CH3), 3.52 (2H, d, J= 5.1 Hz, 
H-5’ and H-5”), 4.70 (1H, m, H-4’), 5.17 (1H, m, H-3’), 6.16 (1H, dd, J= 3.6 and 6.9, H-1’), 
7.52 (1H, d, J= 1.1 Hz, H-6), 11.31 (1H, br s, N(3)H); HRMS (ESI-MS) for C11H15N5O6S 
[M+H]+ found, 346.0818; calcd, 346.0821. 
 
5’-Azido-3’,5’-dideoxy-2’,3’-didehydro--D-thymidine (51) 
To a solution of mesylate ester 50 (420 mg, 1.21 mmol) in THF (15 mL) was added DBU 
(906 L, 6.07 mmol), and the reaction was refluxed at 80 °C during overnight. After cooling 
down, the reaction mixture was poured into NH4Cl (15 mL) solution, and extracted with 
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CH2Cl2 (3 x 25 mL). The organic layers were dried over MgSO4, evaporated and purified by 
column chromatography (CH2Cl2/MeOH 99:1) to yield 290 mg (95%) pure title compound. 
1H NMR (300 MHz, DMSO-d6):  1.77 (3H, d, J= 1.0 Hz, 5-CH3), 3.36 (1H, dd, J= 4.8 and 
13.2 Hz, H-5’), 3.62 (1H, dd, J= 3.3 and 13.2 Hz, H-5”), 5.32 (1H, m, H-4’), 6.03 (1H, dd, J= 
1.5 and 5.7, H-1’), 6.40 (1H, dd, J= 1.5 and 6.0 Hz, H-2”), 6.89 (1H, dd, J= 1.5 and 5.4 Hz, 
H-3’), 7.52 (1H, d, J= 1.1 Hz, H-6), 11.31 (1H, br s, N(3)H); HRMS (ESI-MS) for 
C10H11N5O3Na [M+Na]+ found, 272.0761; calcd, 272.0759. 
 
5’-Amino-3’,5’-dideoxy--D-thymidine (52) 
To a solution of azide 51 (150 mg, 0.6 mmol) in methanol (4 mL) was added 10% Pd/C (15 
mg).and the reaction placed under a H2 atmosphere. After 5 hours, the reaction mixture was 
filtered through a plug of Celite, which was further washed with MeOH and the combined 
filtrates were evaporated to yield pure 52 as a white solid (128 mg, 95%). 
1H NMR (300 MHz, DMSO-d6):  1.70 (1H, m, H-3’), 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 1.89-
2.06 (2H, m, H-2’ and H-3”), 2.27 (1H, m, H-2”), 2.56 (2H, d, J= 5.1 Hz, H-5’ and H-5”), 
4.27 (1H, m, H-4’), 5.98 (1H, dd, J= 5.1 and 6.6, H-1’), 7.41 (1H, d, J= 1.1 Hz, H-6); HRMS 
(ESI-MS) for C10H16N3O3 [M+H]+ found, 226.1188; calcd, 226.1191. 
 
5’-Amino-3’,5’-dideoxy-2’,3’-didehydro--D-thymidine (53) 
To a solution of azide 51 (80 mg, 0.32 mmol) in dry pyridine (4 mL) triphenylphospine (135 
mg, 1.6 mmol) was added. The reaction was stirred for 3 hours at room temperature, 
evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 90:10), to 
afford 65 mg of amine 53 (92%), which was used in the next step without purification. 
1H NMR (300 MHz, DMSO-d6):  1.69 (3H, d, J = 1.2 Hz, 5-CH3), 2.59 (1H, dd, J = 4.7 and 
13.5 Hz, H-5’), 2.70 (1H, dd, J = 4.7 and 13.7 Hz, H-5”), 4.99 (1H, m, H-4’), 5.83 (1H, app 
dt, J = 2.4 and 5.7, H-1’), 6.33 (1H, app dt, J = 1.5 and 6.0 Hz, H-2’), 6.81 (1H, app dt, J = 
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1.5 and 4.9 Hz, H-3’), 7.10 (1H, d, J= 1.2, H-6); 13C NMR (75 MHz, DMSO-d6): .96 (5-
CH3), 45.68 (C-5’), 88.49 (C-1’), 89.41 (C-4’), 109.75 (C-5), 125.37 (C-2’), 135.72 (C-3’), 
137.42 (C-6), 150.53 (C-4), 163.75 (C-2); HRMS (ESI-MS) for C10H14N3O3 [M+H]+ found, 
224.1039; calcd, 224.1035. 
 
1-[(2-Hydroxyethoxy)methyl]thymine (54)  
A mixture of thymine (400 mg, 3.17 mmol), HMDS (16 mL) and ammonium sulphate (16 
mg) was refluxed during 2 hours under nitrogen atmosphere. After cooling to room 
temperature, the mixture was evaporated to dryness and redissolved in acetonitril (32 mL). 
After cooling the mixture to -45 °C, trimethylsilyl triflate (602 L, 3.33 mmol) was added 
dropwise, followed by dropwise addition of dioxolane (470 mg, 6.34 mmol). After 2 hours the 
reaction was allowed to warm to room temperature and stirred overnight. To quench the 
reaction, a saturated aqueous NaHCO3-solution (20 mL) was added at -45 °C. The resulting 
mixture was extracted three times with diethylether (25 mL). The combined organic layers 
were dried over MgSO4 and evaporated to dryness. The crude residue was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to obtain 480 mg (76%) of pure compound 54. 
1H NMR (300 MHz, DMSO-d6):  1.75 (3H, d, J= 1.2 Hz, 5-CH3), 3.45 (4H, m, CH2CH2), 
4.61 (1H, t, J=5.1 Hz, OH), 5.03 (2H, s, OCH2N), 7.54 (1H, d, J= 1.2, H-6), 11.26 (1H, br s, 
N(3)H); HRMS (ESI-MS) for C8H12N2O4 [M+Na]+ found, 223.0721; calcd, 223.0694. 
 
1-[(2-Azidoethoxy)methyl]thymine (55) 
Alcohol 54 (480 mg, 1.82 mmol) was dissolved in anhydrous pyridine (14 mL) and 
methanesulfonyl chloride (183 L, 2.36 mmol) was slowly added at 0 °C. After 2 hours, the 
reaction was quenched with aqueous NaHCO3-solution (10 mL) and the mixture was 
extracted three times with ethyl acetate (20 mL). The combined organic layers were dried 
over MgSO4 and evaporated to dryness. The obtained residue was dissolved in DMF (40 mL) 
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and 1.46 g (22.5 mmol) of NaN3 was added. The reaction mixture was heated at 60 °C during 
the night, evaporated and purified by column chromatography (CH2Cl2/MeOH 97:3), yielding 
393 mg (96%) of 55. 
1H NMR (300 MHz, DMSO-d6):  1.75 (3H, d, J= 1.2 Hz, 5-CH3), 3.39 (2H, t, J= 4.8 Hz, 
CH2O), 4.64 (2H, t, J= 4.8 Hz, CH2N3), 5.07 (2H, s, OCH2N), 7.56 (1H, d, J= 1.2 Hz, H-6), 
11.30 (1H, br s, N(3)H); HRMS (ESI-MS) for C8H12N5O3 [M+H]+ found, 226.0948; calcd, 
226.0940. 
 
1-[(2-Aminoethoxy)methyl]thymine (56) 
To a solution of azide 55 (393 mg, 1.75 mmol) in methanol (15 mL) was slowly added 50 mg 
of 10% Pd/C. The reaction mixture was submitted to a hydrogen atmosphere overnight. After 
filtration of the catalyst over a plug of Celite and evaporation of the solvent in vacuo, 
resulting compound 56 (345 mg, 99%) was obtained and used without further purification. 
1H NMR (300 MHz, DMSO-d6):  1.77 (3H, s, 5-CH3), 2.65 (2H, t, J= 5.7 Hz, CH2NH2), 
3.43 (2H, t, J= 4.8 Hz, CH2O), 5.05 (2H, s, OCH2N), 7.48 (1H, s, H-6); HRMS (ESI-MS) for 
C8H14N3O3 [M+H]+ found, 200.1034; calcd, 200.1035. 
 
N-[(Thymin-1-yl)methoxyethyl]-N’-phenylthiourea (31) 
The title compound was synthesized from 56 (65 mg, 0.33 mmol) and phenyl isothiocyanate 
(57 mg, 0.42 mmol) in 2 mL DMF using the same procedure as described for the synthesis of 
10. After purification by column chromatography (CH2Cl2/MeOH 99:1), thiourea 31 (94 mg, 
86%) was obtained as a white powder. 
1H NMR (300 MHz, DMSO-d6):  1.74 (3H, d, J= 0.9 Hz, 5-CH3), 3.62 (4H, app s, CH2CH2), 
5.06 (2H, s, OCH2N), 7.07 (1H, m, arom H), 7.28 (2H, m, 2 arom H), 7.37 (2H, d, J= 7.5 Hz, 
2 arom H), 7.56 (1H, d, J= 1.2 Hz, H-6), 7.76 (1H, br s, N(5’)H), 9.61 (1H, br s, N(ar)H), 
11.28 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6): 12.56 (5-CH3), 44.10 (CH2NH’), 
 28
67.35 (CH2O), 76.84 (OCH2N), 109.92 (C-5), 123.79 (arom C), 124.93 (arom C), 129.33 
(arom C), 139.77 (C-6), 141.23 (arom C), 151.78 (C-4), 164.98 (C-2), 181.18 (C=S); HRMS 
(ESI-MS) for C15H19N4O3S [M+H]+ found, 335.1175; calcd, 335.1177. Anal. (C15H18N4O3S) 
C, H, N. 
 
N-(5’-Deoxy-2’,3’-O-isopropylideneadenosin-5’-yl)-N’-(-D-thymidin-5’-yl)thiourea (58) 
5’-Amino-2’,3’-O-isopropylidene adenosine (57) (130 mg, 0.43 mmol), imidazole (6mg, 0.08 
mmol) and 1,1-thiocarbonyldiimidazole (83 mg, 0.47 mmol) were dissolved in DMF (7 mL) 
at 0 °C and after 10 minutes the reaction was allowed to warm up to room temperature. After 
2 hours, 49 (112 mg, 0.43 mmol) in 2 mL of DMF was added. After 3 hours, the reaction was 
finished and evaporated to dryness. The obtained crude compound was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to obtain 205 mg (82%) 58. 
1H NMR (300 MHz, DMSO-d6):  1.32 (3H, s, CCH3 (A)), 1.53 (3H, s, CCH3 (A)), 1.76 (3H, 
d, J= 0.9 Hz, 5-CH3 (T)), 1.87-1.94 (2H, ddd, J= 2.6 and 14.2 Hz, H-2’ (T)), 2.49-2.59 (1H, 
m, H-2” (T)), 3.41-3.67 (3H, m, H-5’(T), H-5” (T) and H-5’ (A)), 3.78-3.90 (1H, m, H-5” 
(A)), 4.13-4.34 (3H, m, H-3’ (T), H-4’ (T) and H-4’ (A)), 5.01 (1H, dd, J= 3.4 and 6.2 Hz, H-
3’ (A)), 5.41 (1H, d, J= 3.4 Hz, 3’-OH (T)), 5.46 (1H, dd, J= 2.8 and 6.3 Hz, H-2’ (A)), 6.15 
(2H, m, H-1’ (T) and H-1’ (A)), 7.34 (2H, s, NH2), 7.55 and 7.64 (2H, 2 x br s, 2 x N(5’)H), 
7.73 (1H, d, J= 1.2 Hz, H-6), 8.18 and 8.33 (2H, 2 x s, H-2 and H-8 (A)), 11.24 (1H, br s, 
N(3)H); HRMS (ESI-MS) for C24H32N9O7S [M+H]+ found, 390.2148; calcd, 390.2145. 
 
N-(5’-Deoxyadenosin-5’-yl)-N’-(-D-thymidin-5’-yl)thiourea (33) 
Compound 58 (120 mg, 0.20 mmol) was dissolved in 50% trifluoroacetic acid in H2O (10 
mL) and stirred for 2 hours at room temperature. The reaction mixture was evaporated to 
dryness and purified by column chromatography (CH2Cl2/MeOH 93:7) to obtain 98 mg of 
pure title compound (89%). 
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1H NMR (300 MHz, DMSO-d6):  1.76 (3H, d, J= 1.2 Hz, 5-CH3 (T)), 1.86-1.94 (2H, ddd, J= 
2.6 and 14.6 Hz, H-2’ (T)), 2.49-2.59 (1H, m, H-2” (T)), 3.41-3.67 (3H, m, H-5’(T), H-5” (T) 
and H-5’ (A)), 3.82-3.93 (1H, m, H-5” (A)), 4.01-4.29 (4H, m, H-3’ (T), H-4’ (T), H-4’ (A) 
and H-3’ (A)), 4.70 (1H, t, J= 5.4 Hz, H-2’ (A)), 5.29 (1H, br s, 3’-OH (A), 5.43 (1H, br s, 3’-
OH (T)), 5.49 (1H, br s, 2’-OH (A)), 5.88 (1H, d, J= 6.0 Hz, H-1’ (A)), 6.14 (1H, dd, J= 3.0 
and 7.5 Hz, H-1’ (T)), 7.43 (2H, s, NH2), 7.59 (1H, br s, N(5’)H), 7.74 (2H, app d, J= 1.2 Hz, 
H-6 and N(5’(A)H)), 8.20 and 8.38 (2H, 2 x s, H-2 and H-8 (A)), 11.25 (1H, br s, N(3)H); 
HRMS (ESI-MS) for C21H28N9O7S [M+H]+ found, 550.1833; calcd, 550.1832. Anal. 
(C21H27N9O7S) C, H, N. 
 
Supporting Information Available: Experimental section and analytical data for 
intermediates (40-45) and final products (3-8, 11-22, 24-25, 27-30, 32) and elemental analysis 
of final products. Also provided is a more detailed explanation of the computational 
methodology. This material is available free of charge via the Internet at http://pubs.acs.org. 
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Figure and Scheme Legends  
Figure 1. Dinucleoside 1 (Ki = 37 M) and envisaged analogues 
Figure 2. Inverse sugar binding of 3’-C-arylthiourea-modified β-thymidines and anticipated 
similar relative orientation of the coloured moieties in 5’-deoxy-5’-arylthiourea modified α-
thymidines. 
Figure 3. Comparison of the parallel synthesized - and - thiourea derivatives;(■ -
derivatives, ■ -derivatives). 
Figure 4. Compound 2 (left) and compound 10 (right) docked in the active site of TMPKmt. 
All residues interacting with the inhibitors (hydrophobic contact) are shown as well as the 
hydrogen bonding parttern (calculated using Ligplot and HBPlus32, 33). Drawings created 
using Molscript.34 
Figure 5. Docking and superposition of α-derivatives 10 (green carbons) and 24 (grey 
carbons) in the active site of TMPKmt, 24 having a longer linker (n=2). The phenyl tails of 
the inhibitors point to the front and seem to exit the enzyme through a channel lined up by 
residues Arg14, Ala35, Phe36, Pro37, Tyr39, Arg160. The “channel” residues are coloured 
blue. Picture created using Molscript,35 Bobscript,36 Raster3D.37 
 
Scheme 1. Synthesis of 3’-C-branched--thioureaderivatives 2-8. Reagents and conditions: 
(a) Bu3SnCH=CHPh, AIBN, benzene, reflux, 72h, 24%; (b) (i) 4-MNO, OsO4, dioxane, rt, 
16h; (ii) NaIO4, rt, 2h; (iii) NaBH4, EtOH/H2O, rt, 2h, 59%; (c) (i) MsCl, pyridine, 0 °C, 1h; 
(ii) NaN3, DMF, 60 °C, 7h, 97%; (d) Pd/C, H2, MeOH, rt, 3h, 99%; (e) 3-R2-4-R1-
phenylisothiocyanate, DMF, 0 °C, 1h, 70-88%; (f) TBAF, THF, rt, 1h, 87-92% . 
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Scheme 2. Synthesis of -D-thymidine 5’-O-monophosphate 9. Reagents and conditions: (a) 
NH3, MeOH, rt, 16h, 98%; (b) POCl3, P(OMe)3, 0 °C, 4h; then rt, 0.5h, 62%. 
Scheme 3. Synthesis of 5’-substituted -thymidine derivatives 10-27, 30. Reagents and 
conditions: (a) (i) MsCl, pyridine, 0 °C, 1h (ii) NaN3, DMF, 60 °C, 16h, 68%; (b) H2, Pd/C, 
MeOH, rt, 6h, 98%; (c) suitable iso(thio)cyanate, DMF, 71-91%; or: suitable amine, 1,1’-
TCDI, DMF, rt, 3h, 75-82%. 
Scheme 4. Synthesis of 3’-deoxy- and 3’-deoxy-2’,3’didehydro--thymidinederivatives 28 
and 29. Reagents and conditions: (a) MsCl, Pyridine, 0 °C, 2h, 81%; (b) DBU, THF, 80 °C, 
16h, 95%; (c) H2, Pd/C, MeOH, rt, 5h, 95%; (d) PPh3, Pyridine, rt, 3h, 92% (e) 3-CF3-4-Cl-
phenylisothiocyanate, DMF, rt, 3h, 78%. 
Scheme 5. Synthesis of acyclic derivatives 31 and 32. Reagents and conditions: (a) silylated 
thymine, TMSOTf, acetonitrile, -45 °C for 2h then rt, 16h, 76 %; (b) (i) MsCl, pyridine, 0 °C, 
2h (ii) NaN3, DMF, 60 °C, 16h, 96%; (c) Pd/C, H2, MeOH, rt, 16h, 99%; (d) 3-R2-4-R1-
phenylisothiocyanate, DMF, rt, 3h, 83-86%. 
Scheme 6. Synthesis of adenosine conjugate 33. Reagents and conditions: (a) 5’-deoxy-5’-
NH2-α-thymidine (49), TCDI, DMF, rt, 2h; (b) 50% TFA, rt, 2h, 73%. 
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Table 1: Kinetic parameters of TMPKmt with compounds 1-8 
O
O T
HN
HO
OT
NH
OH
O
HO
N NH
O
O
NH
H
N
S
R1
R2
2-81  
Compound R1 R2 Ki (M) TMPK 
mt 
Ki (M) 
TMPK h 
MCC 
Vero cell  
cultures a 
dTMP   4.5b 5 b  
1   37.0 > 1000  
2 H H 69.0   
3 Cl H 21.0  > 100 
4 OCH3 H 46.0  > 100 
5 CH3 H 36.0  > 100 
6 Cl Cl 7.2  > 100 
7 OCH2Ph H 12.0  > 100 
8 Cl CF3 5.0 > 1000 > 100 
 
a Minimum cytotoxic concentration in Vero cell cultures, i.e. the concentration required to 
cause microscopically detectable alteration of normal cell morphology. 
b Km-Value 
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Table 2: Kinetic parameters of TMPKmt with compounds 9-33 and 48-49 
HO
O
NH N NH
O
OH
N
X
30, 48-49
HO
O
R N NH
O
O
10-29,33
R
H
N
N
OO
O
NH
H
NR
S
31-32
Compound R X Ki (M) TMPK mt
Ki (M) 
TMPK h SI 
MIC99 (g/ml) 
 (M. bovis) 
% Inh  
(M. tub H37Rv)d
MCC M 
Vero cell culturese
dTMP   4.5 a 5.0 a     
α-dTMP   15.0      
10 Phenyl S 16.0     > 100 
11 4-Cl-phenyl S 3.2 > 1000     
12 4-MeO-phenyl S 10.0      
13 4-Me-phenyl S 7.8      
14 3,4-diCl-phenyl S 1.0 274 270 25 38% > 100 
15 3-CF3-4-Cl-phenyl S 0.6 362 600 20 39% > 100 
16 4-morpholinophenyl S 19.2      
17 1-adamantyl S 15.0     > 100 
18 3-pyridyl S 18.0      
19 Flouresceinyl S 5.4   > 150   
20 Phenylmethyl S 5.4      
21 Benzhydryl S 4.9 > 500    > 100 
22 Benzoyl S 7.2      
23 3-CF3-4-Cl-phenylmethyl S 2.6 50 20 40  > 100 
24 Phenylethyl S 3.8 > 800    > 100 
25 3,4-diCl-phenylethyl S 2.2 79 40 50  > 100 
26 3,4-diCl-phenyl O 1.1 116 105 40 (MIC50) 41%  
27 3-CF3-4-Cl-phenyl O 1.9 166 90 40 (MIC50) 49%  
28 b 3-CF3-4-Cl-phenyl S 2.3 > 500  40 34%  
29c 3-CF3-4-Cl-phenyl S 3.8 190 50 100 55%  
30 Benzamido  35      
31 Phenyl S 260     > 100 
32 3-CF3-4-Cl-phenyl S 37.0    34% 100 
33 5’-deoxy-β-D-adenosin-5’-yl S 26 280 10    
48 N3  26.5      
49 NH2  16.0   > 40 g/ml   
a Km-Value; b 3’-deoxy-ribonucleoside; c 3’-deoxy-2’,3’-didehydronucleoside; d inhibition at 6.25 g/mL; e 
Minimum cytotoxic concentration in Vero cell cultures, i.e. the concentration required to cause microscopically 
detectable alteration of normal cell morphology. 
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